『Beta Finch - Eli Lilly - LLY - EN』のカバーアート

Beta Finch - Eli Lilly - LLY - EN

Beta Finch - Eli Lilly - LLY - EN

著者： Beta Finch
無料で聴く

AI-powered earnings call analysis for Eli Lilly (LLY). Two AI hosts break down quarterly results, key metrics, and market implications in digestible podcast episodes.2026 Beta Finch 個人ファイナンス 経済学
エピソード
  • Eli Lilly Q1 2026 Earnings Analysis

    Eli Lilly Q1 2026 Earnings Analysis
    2026/04/30
    # Beta Finch Podcast Script - Eli Lilly Q1 2026 Earnings

    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and I'm joined as always by my co-host Jordan. Today we're diving into Eli Lilly's first quarter 2026 results - and wow, what a quarter this was. Jordan, before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN:** Thanks Alex. And you're absolutely right about this being a wow quarter. Lilly just posted some absolutely staggering numbers. We're talking about 56% revenue growth year-over-year, bringing in what appears to be massive incretin revenues. But what really caught my attention was their guidance raise - they bumped up their full-year revenue expectations by $2 billion to between $82 and $85 billion.

    **ALEX:** That's incredible. Let me put that in perspective for our listeners - the midpoint of that guidance represents 28% growth for the full year. For a company of Lilly's size, that's just phenomenal. And the driving force here is clearly their GLP-1 portfolio - Mounjaro and Zepbound combined brought in $12.8 billion in global revenue just in Q1, contributing $6.7 billion of growth compared to last year.

    **JORDAN:** What's fascinating is how this growth is playing out globally. We saw really strong international momentum for Mounjaro. In markets like Brazil and Korea, they're claiming around 60% market share. And here's something interesting - they mentioned that generic semaglutide entry in some markets like India actually seems to be stimulating overall market growth rather than hurting Lilly's position.

    **ALEX:** That's a great point about the generics. CEO Dave Ricks made a really insightful comment during the Q&A about how this obesity market behaves differently from traditional pharma categories. He said that because so much of the business is out-of-pocket - 75% of ex-US Mounjaro business and a meaningful portion in the US - they see "quite expansionary volume" when they reduce prices. It's almost like the demand curve is more elastic than typical prescription drugs.

    **JORDAN:** Exactly. And speaking of new developments, let's talk about Koundeo - their newly approved oral GLP-1. This is huge because it's the first new incretin medicine launched with obesity as the primary indication, not diabetes. They mentioned having over 20,000 patients treated already with about 80% being new to the class entirely.

    **ALEX:** The Koundeo launch strategy is really interesting. They're taking a measured approach - they started with digital campaigns, moved to in-person physician promotion, and they're planning full-scale direct-to-consumer TV advertising in Q3. What I found telling was that they already have over 8,000 prescribers, with a third of them never having prescribed an oral GLP-1 before.

    **JORDAN:** And the access piece is critical. They've secured commercial access at two of the three largest pharmacy benefit managers, effective mid-May. Plus, the Medicare Bridge program extension through 2027 could be a game-changer - we're talking about $50 monthly copays for seniors. When an analyst asked about Medicare activation, management indicated this will be a gradual build through 2026 and into 2027.

    **ALEX:** Let's talk about their pipeline because they were incredibly busy on the R&D front. They announced four acquisitions this quarter - Orna Therapeutics for autoimmune CAR-T therapies, Centessa for sleep disorders, Colonia for cancer treatments, and Ajax for blood cancers. Plus they had positive Phase III data for multiple programs.

    **JORDAN:** The retatrutide data particularly caught my eye. This is their triple agonist - GIP, GLP-1, and glucagon. In the TRANSCEND T2D1 trial, patients lost an average of 25 to 37 pounds while also

    This episode includes AI-generated content.
    続きを読む 一部表示
    8 分
  • Eli Lilly Q4 2025 Earnings Analysis

    Eli Lilly Q4 2025 Earnings Analysis
    2026/02/22
    **Beta Finch Podcast Script: Eli Lilly Q4 2025 Earnings**

    ---

    **ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and joining me as always is Jordan. Today we're diving into Eli Lilly's blockbuster Q4 2025 results - and folks, when I say blockbuster, I mean it. This pharmaceutical giant just delivered some truly staggering numbers.

    But before we jump in, I need to share our standard disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN**: Thanks Alex. And wow, where do we even start with these numbers? Lilly just reported 45% full-year revenue growth - that's not a typo, folks - forty-five percent. We're talking about $65.2 billion in revenue for 2025, with earnings per share jumping 86% to $24.21.

    **ALEX**: It's almost surreal when you see numbers like that from a major pharma company. Jordan, what's driving this incredible performance?

    **JORDAN**: It all comes down to one word: incretins. These are the diabetes and obesity drugs that have become absolute juggernauts. Their key products - we're talking Mounjaro, Zepbound, and their international rollouts - generated over $13 billion in Q4 revenue alone and grew 91% compared to the same quarter last year.

    **ALEX**: Let's break that down for our listeners. Mounjaro is their diabetes drug, Zepbound is the obesity treatment, but they're essentially the same molecule - tirzepatide - just branded differently for different conditions. And the demand has been absolutely explosive.

    **JORDAN**: Exactly. What's fascinating is how they've captured market leadership. In the US, Mounjaro now has over 55% of new prescriptions in the diabetes incretin market, while Zepbound commands nearly 70% share in the branded obesity market. But here's what really caught my attention - they're not just winning in the US anymore.

    **ALEX**: Right, their international business has been crushing it. CEO David Ricks mentioned they're now the incretin market share leader outside the US as well. That's a huge development because historically, US pharma companies have struggled to replicate their domestic success internationally, especially in obesity treatments.

    **JORDAN**: And they're not slowing down. Looking ahead to 2026, management guided to revenue between $80-83 billion. That's another 25% growth at the midpoint. But here's where it gets interesting - they're expecting significant pricing headwinds.

    **ALEX**: This is crucial for investors to understand. Lilly is projecting price declines in the low-to-mid teens for 2026. That's a massive headwind, but they believe volume growth will more than offset it.

    **JORDAN**: The pricing pressure comes from several factors. First, they struck a deal with the US government to provide obesity medicines to Medicare patients for just $50 per month out-of-pocket starting no later than July 1st. That's huge for patient access but means lower prices for Lilly.

    **ALEX**: They're also facing competition from oral versions of these drugs. During the call, they discussed launching their own oral obesity treatment, orforglipron, which they expect to get FDA approval for in Q2 2026.

    **JORDAN**: The oral competition point is really interesting. When Novo Nordisk launched oral Wegovy recently, instead of cannibalizing existing injectable sales, it actually expanded the overall market. Lilly's management seems confident this trend will continue - that oral options bring new patients into treatment rather than just switching existing ones.

    **ALEX**: Let's talk about their direct-to-consumer business because this is revolutionary for pharma. They've reached 1 million patients on their US direct-to-patient platform. Think about that - patients are buying prescription obesity drugs directly from the manufacturer, often payin

    This episode includes AI-generated content.
    続きを読む 一部表示
    1 分
  • Eli Lilly Q4 2024 Earnings Analysis

    Eli Lilly Q4 2024 Earnings Analysis
    2026/02/22
    **BETA FINCH PODCAST SCRIPT**

    ---

    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we turn complex corporate calls into clear insights. I'm Alex.

    **JORDAN:** And I'm Jordan. Today we're diving into Eli Lilly's Q4 2024 earnings - and wow, what a quarter for the pharmaceutical giant.

    **ALEX:** Before we jump in, I need to share an important disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN:** Absolutely crucial reminder there. Now Alex, let's talk numbers because Lilly absolutely crushed it this quarter.

    **ALEX:** They really did, Jordan. Revenue grew 45% in Q4 alone, and for the full year, they posted 32% growth. But here's the kicker - they exceeded their initial guidance by $4 billion. That's not a small miss on the upside, that's a massive beat.

    **JORDAN:** And when you dig into what's driving this growth, it's really the incretin story - Mounjaro and Zepbound. Global Mounjaro sales hit $3.5 billion in Q4, while US Zepbound brought in $1.9 billion. These are the diabetes and obesity drugs that everyone's talking about.

    **ALEX:** What I found fascinating in the call was CEO Dave Ricks addressing what he called the "turbulence" around demand predictions. There's been this narrative that maybe the obesity market isn't as big as everyone thought, with prescription growth slowing and supply catching up faster than expected.

    **JORDAN:** Right, and one analyst - Steve Scala - basically asked the uncomfortable question everyone's thinking: "Are we all over our skis on this market?" But Ricks pushed back hard, saying they still believe this is a market with hundreds of millions of people globally and they're still gating promotion and launches because they can't make enough.

    **ALEX:** That confidence is backed up by some interesting data points. Zepbound actually became the market leader in anti-obesity prescriptions in Q4, and they're seeing strong adherence rates - better than competitors in some cases.

    **JORDAN:** Speaking of competition, let's talk about what's coming next because this is where it gets really interesting. They have Orforglipron, which is their oral GLP-1 drug, potentially launching in 2026. This could be a game-changer because it doesn't require refrigeration and addresses the 20-25% of patients who have needle phobia.

    **ALEX:** The development timeline for Orforglipron is aggressive too. They're expecting multiple readouts in 2025 - up to five studies in diabetes and two in obesity. Dan Skovronsky, their Chief Scientific Officer, said they're aiming for efficacy similar to injectable single-acting GLP-1s, which would put it in the Ozempic range rather than the tirzepatide range.

    **JORDAN:** But here's what I found most intriguing - they're not just staying in their lane. They're exploring incretins for brain health, substance use disorders, pain, and inflammation. They're essentially asking: "What else can these molecules do?"

    **ALEX:** The pipeline is incredibly robust. Eight new Phase III programs started in 2024, and they're planning more for 2025. They're also expecting data from the tirzepatide cardiovascular outcomes study in Q3, which could be huge for reimbursement.

    **JORDAN:** Let's talk margins because this is where Lilly is really showing operational leverage. Gross margins hit 83.2% in Q4, and they're guiding for 340 basis points of operating margin expansion in 2025. That's massive.

    **ALEX:** CFO Lucas Montarce made an interesting comment about long-term margins though. They're not chasing the 50% operating margins that some analysts are projecting for the end of the decade. They believe reinvesting in R&D is more important for sustainable growth, keeping them in the low 40s range.

    **JORDAN:** Smart approach, especially when you look at

    This episode includes AI-generated content.
    続きを読む 一部表示
    1 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません